United Therapeutics Target of Unusually High Options Trading (NASDAQ:UTHR)

United Therapeutics Corporation (NASDAQ:UTHR) was the recipient of some unusual options trading activity on Monday. Stock investors purchased 16,791 call options on the stock. This represents an increase of 789% compared to the average volume of 1,888 call options.

Insiders Place Their Bets

In other news, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $529.95, for a total transaction of $4,398,585.00. Following the completion of the transaction, the executive vice president directly owned 45,172 shares in the company, valued at $23,938,901.40. This represents a 15.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction dated Thursday, March 26th. The shares were sold at an average price of $535.90, for a total value of $5,359,000.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at $10,115,648.40. The trade was a 34.63% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 333,820 shares of company stock valued at $165,495,478 in the last three months. 10.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On United Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP lifted its stake in shares of United Therapeutics by 74.5% during the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after buying an additional 1,042,711 shares during the last quarter. Darwin Global Management Ltd. bought a new stake in shares of United Therapeutics during the 3rd quarter worth about $317,617,000. Norges Bank acquired a new position in United Therapeutics in the 4th quarter valued at about $293,418,000. Invesco Ltd. grew its stake in United Therapeutics by 90.2% in the 2nd quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock valued at $254,219,000 after buying an additional 419,588 shares during the last quarter. Finally, Avoro Capital Advisors LLC raised its holdings in United Therapeutics by 17.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after acquiring an additional 383,838 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Stock Up 0.8%

UTHR opened at $592.98 on Wednesday. United Therapeutics has a 12-month low of $266.98 and a 12-month high of $607.89. The business has a 50 day moving average of $500.92 and a 200-day moving average of $476.29. The stock has a market cap of $25.99 billion, a price-to-earnings ratio of 21.25, a PEG ratio of 2.12 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business had revenue of $790.20 million for the quarter, compared to analyst estimates of $814.80 million. During the same period in the previous year, the firm earned $6.19 EPS. The firm’s revenue was up 7.4% compared to the same quarter last year. As a group, analysts expect that United Therapeutics will post 24.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on UTHR shares. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. TD Cowen increased their price objective on United Therapeutics from $575.00 to $660.00 and gave the company a “buy” rating in a report on Monday. HC Wainwright raised their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Royal Bank Of Canada boosted their target price on shares of United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Nine research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $586.00.

Key Stories Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: TETON‑1 Phase 3 success — The pivotal TETON‑1 study met its primary endpoint, showing a clinically meaningful FVC improvement (Hodges‑Lehmann estimate ~130.1 mL vs placebo at 52 weeks), supporting Tyvaso’s potential expansion into IPF and a likely regulatory path. BusinessWire: TETON‑1 Results
• Positive Sentiment: Wall Street upgrades and target lifts — Multiple firms raised price targets (TD Cowen, HC Wainwright, BofA, TD Cowen to ~$660 among others), reflecting materially higher revenue/market‑expansion assumptions if Tyvaso wins an IPF label. TickerReport: HC Wainwright Raise
• Positive Sentiment: Buyback / ASR and ralinepag momentum — Recent company buyback authorizations (including accelerated share repurchase activity) and positive Phase 3 ralinepag data (PAH) add to near‑term shareholder‑return dynamics and reduce share count risk. QuiverQuant: Buyback & Ralinepag
• Neutral Sentiment: Heavy call‑option activity and volume — Unusually large call buying and above‑average equity volume indicate speculative positioning and short covering; this can amplify moves short term but is not a fundamental read‑through by itself.
• Neutral Sentiment: Mixed analyst stances — Some firms raised targets but kept neutral/equal‑weight ratings (e.g., Wells Fargo, BofA), signaling differing views on how much IPF uptake and pricing convert to durable earnings. 24/7 Wall St.: Dual Target Hikes
• Negative Sentiment: Valuation and execution risk cautions — Some analysts note that strong trial momentum is partially offset by high valuation and execution/regulatory risk (commercial rollout, payer uptake), which could limit further multiple expansion. TipRanks: Balanced View
• Negative Sentiment: Large insider selling flagged — Public filings compiled by data providers show extensive insider sales over recent months; investors often view concentrated insider selling as a negative signal to monitor. QuiverQuant: Insider Activity
• Negative Sentiment: Questions about sustainability of the move — Some market commentaries (and earnings‑estimate trends) warn the post‑trial pop may not sustain unless follow‑on commercialization, label, and payer access dynamics become clearer. Zacks: Will Strength Last?

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.